| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
168 |
165 |
$1K |
| 87631 |
|
153 |
149 |
$838.67 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
445 |
318 |
$795.87 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
406 |
318 |
$294.80 |
| 87640 |
|
406 |
318 |
$265.32 |
| 87500 |
|
403 |
315 |
$265.32 |
| 87641 |
|
403 |
315 |
$265.32 |
| 87653 |
|
399 |
317 |
$265.32 |
| 87481 |
|
145 |
139 |
$265.28 |
| 87541 |
|
153 |
149 |
$206.36 |
| 87498 |
|
153 |
149 |
$206.36 |
| 87581 |
|
153 |
149 |
$206.36 |
| 87486 |
|
153 |
149 |
$206.36 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
40 |
28 |
$49.59 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
118 |
71 |
$32.65 |
| 83550 |
|
53 |
27 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
18 |
15 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
15 |
15 |
$0.00 |
| 82607 |
|
43 |
27 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
85 |
48 |
$0.00 |
| P9603 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled |
18 |
15 |
$0.00 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
57 |
40 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
47 |
29 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
51 |
32 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
65 |
34 |
$0.00 |
| 81003 |
|
18 |
14 |
$0.00 |
| 87150 |
|
57 |
40 |
$0.00 |
| 83540 |
|
54 |
28 |
$0.00 |
| 84550 |
|
14 |
13 |
$0.00 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
40 |
28 |
$0.00 |
| 80061 |
Lipid panel |
87 |
53 |
$0.00 |
| 84439 |
|
22 |
12 |
$0.00 |
| 84481 |
|
22 |
12 |
$0.00 |
| 81002 |
|
23 |
22 |
$0.00 |